Head-To-Head Comparison: Windtree Therapeutics (WINT) versus SIGA Technologies (SIGA)

Windtree Therapeutics (OTCMKTS: WINT) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

0.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are owned by institutional investors. 3.5% of Windtree Therapeutics shares are owned by insiders. Comparatively, 4.7% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Windtree Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Windtree Therapeutics and SIGA Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
SIGA Technologies 0 0 0 0 N/A

Profitability

This table compares Windtree Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
SIGA Technologies -201.85% N/A -23.22%

Earnings and Valuation

This table compares Windtree Therapeutics and SIGA Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 8.06 -$39.49 million ($3.59) -0.07
SIGA Technologies $14.99 million 25.53 -$39.69 million ($0.53) -9.15

Windtree Therapeutics has higher earnings, but lower revenue than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

SIGA Technologies beats Windtree Therapeutics on 7 of the 9 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About SIGA Technologies

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Receive News & Ratings for Windtree Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply